NCT07521358Completed
Magnesium Supplementation With Fluoxetine for Cognitive Function in Depression
Effects of Magnesium Supplementation on Serum Brain-Derived Neurotrophic Factor Levels and Cognitive Function in Patients With Depression Receiving Fluoxetine Therapy
Source: ClinicalTrials.gov · Last updated 9 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether magnesium supplementation can improve cognitive function in patients with depression receiving fluoxetine therapy. It also aims to assess its effect on serum brain-derived neurotrophic factor (BDNF) levels in adult patients with depression. The main questions it aims to answer are: * Does magnesium supplementation improve cognitive function in patients with depression receiving fluoxetine? * Does magnesium supplementation increase serum BDNF levels in these patients? Researchers will compare patients receiving fluoxetine with magnesium supplementation to those receiving fluoxetine alone to determine whether magnesium provides additional benefits. Participants will: * Receive fluoxetine therapy with or without magnesium supplementation for 6 weeks * Undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) at baseline and after treatment * Provide blood samples for measurement of serum BDNF levels at baseline and after 6 weeks
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 3 Apr 2026
- Start date
- 1 Jul 2025
- Primary completion date
- 1 Aug 2025
- Lead sponsor
- Hasanuddin University
- Diseases
- Depression
- NCT number
- NCT07521358
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 1 Jul 2025 to the primary completion date, 1 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of other psychotropic medications that may affect cognitive function
Other illness
- History of other major psychiatric disorders (e.g., schizophrenia, bipolar disorder)
- Severe medical or neurological illness
Lab values
- Known hypersensitivity to magnesium
Other
- Pregnancy or breastfeeding
- Inability to complete cognitive assessment
Who the study is looking for
- Adult patients aged 18-60 years
- Diagnosed with major depressive disorder based on clinical assessment
- Receiving fluoxetine therapy
- Able to understand and provide informed consent
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dr. Wahidin Sudirohusodo Hospital Coordinator of this site? Confirm its status | Makassar | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.